Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Ampligen for post-COVID conditions has completed and posted results, reporting efficacy and safety data for AIM ImmunoTech's candidat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Post-covid-19 Condition

Drugs mentioned

• Ampligen (rintatolimod)

Snippet

Sponsor: AIM ImmunoTech Inc. | Conditions: Post COVID-19 Condition, Long COVID | Phase 2 | Status: COMPLETED | Results posted: 2025-01-22